🎉 M&A multiples are live!
Check it out!

Natco Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Natco Pharma and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Natco Pharma Overview

About Natco Pharma

Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.


Founded

1981

HQ

India
Employees

4.8K+

Financials

LTM Revenue $526M

LTM EBITDA $257M

EV

$1.4B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Natco Pharma Financials

Natco Pharma has a last 12-month revenue of $526M and a last 12-month EBITDA of $257M.

In the most recent fiscal year, Natco Pharma achieved revenue of $462M and an EBITDA of $217M.

Natco Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Natco Pharma valuation multiples based on analyst estimates

Natco Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $313M $462M XXX XXX XXX
Gross Profit $142M $227M XXX XXX XXX
Gross Margin 45% 49% XXX XXX XXX
EBITDA $120M $217M XXX XXX XXX
EBITDA Margin 38% 47% XXX XXX XXX
Net Profit $19.7M $83.1M XXX XXX XXX
Net Margin 6% 18% XXX XXX XXX
Net Debt $35.9M $4.9M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Natco Pharma Stock Performance

As of April 15, 2025, Natco Pharma's stock price is INR 775 (or $9).

Natco Pharma has current market cap of INR 139B (or $1.6B), and EV of INR 116B (or $1.4B).

See Natco Pharma trading valuation data

Natco Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.4B $1.6B XXX XXX XXX XXX $1.30

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Natco Pharma Valuation Multiples

As of April 15, 2025, Natco Pharma has market cap of $1.6B and EV of $1.4B.

Natco Pharma's trades at 2.6x LTM EV/Revenue multiple, and 5.3x LTM EBITDA.

Analysts estimate Natco Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Natco Pharma and 10K+ public comps

Natco Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.4B XXX XXX XXX
EV/Revenue 2.7x XXX XXX XXX
EV/EBITDA 5.5x XXX XXX XXX
P/E 7.5x XXX XXX XXX
P/E/Growth -0.3x XXX XXX XXX
EV/FCF 8.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Natco Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Natco Pharma Valuation Multiples

Natco Pharma's NTM/LTM revenue growth is 9%

Natco Pharma's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $38K for the same period.

Over next 12 months, Natco Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Natco Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Natco Pharma and other 10K+ public comps

Natco Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 48% XXX XXX XXX XXX
EBITDA Margin 49% XXX XXX XXX XXX
EBITDA Growth 81% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 58% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $38K XXX XXX XXX XXX
S&M Expenses to Revenue 4% XXX XXX XXX XXX
G&A Expenses to Revenue 3% XXX XXX XXX XXX
R&D Expenses to Revenue 4% XXX XXX XXX XXX
Opex to Revenue 39% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Natco Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Natco Pharma M&A and Investment Activity

Natco Pharma acquired  XXX companies to date.

Last acquisition by Natco Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Natco Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Natco Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Natco Pharma

When was Natco Pharma founded? Natco Pharma was founded in 1981.
Where is Natco Pharma headquartered? Natco Pharma is headquartered in India.
How many employees does Natco Pharma have? As of today, Natco Pharma has 4.8K+ employees.
Who is the CEO of Natco Pharma? Natco Pharma's CEO is Mr. Rajeev Nannapaneni.
Is Natco Pharma publicy listed? Yes, Natco Pharma is a public company listed on BOM.
What is the stock symbol of Natco Pharma? Natco Pharma trades under 524816 ticker.
When did Natco Pharma go public? Natco Pharma went public in 1995.
Who are competitors of Natco Pharma? Similar companies to Natco Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Natco Pharma? Natco Pharma's current market cap is $1.6B
What is the current revenue of Natco Pharma? Natco Pharma's last 12-month revenue is $526M.
What is the current EBITDA of Natco Pharma? Natco Pharma's last 12-month EBITDA is $257M.
What is the current EV/Revenue multiple of Natco Pharma? Current revenue multiple of Natco Pharma is 2.6x.
What is the current EV/EBITDA multiple of Natco Pharma? Current EBITDA multiple of Natco Pharma is 5.3x.
What is the current revenue growth of Natco Pharma? Natco Pharma revenue growth between 2023 and 2024 was 48%.
Is Natco Pharma profitable? Yes, Natco Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.